Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Diamyd Medical AB

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Phase IIb Topline Results Demonstrate a Significant Treatment Effect of Diamyd® in Type 1 Diabetes

              Contact the Supplier

              Lead Product(s): GAD-alum

              Therapeutic Area: Endocrinology Product Name: Diamyd

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 14, 2020

              Details:

              In line with previous large-scale analysis of trials involving subcutaneous administration of Diamyd®, the reults, encompassing a total of 109 patients, showed a statistically significant effect in the predefined HLA (Human Leukocyte Antigen) subgroup of trial participants.

              Diamyd Medical AB

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Diamyd Medical's Analysis of Prevention Trials and Intralymphatic Pilot Trial with the Diabetes Vaccine Diamyd® Support a Positive Trend in...

              Contact the Supplier

              Lead Product(s): GAD-alum

              Therapeutic Area: Endocrinology Product Name: Diamyd

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 01, 2020

              Details:

              The analysis while not reaching statistical significance, supports a positive effect of subcutaneous injections of Diamyd® on delaying the progression to type 1 diabetes in HLA-type DR3-DQ2 group while no benefit vs placebo is seen in individuals negative for HLA-type DR3-DQ2.

              Diamyd Medical AB

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Diabetologia Publishes Results Highlighting Efficacy of the Diabetes Vaccine Diamyd® in Genetically Defined Subgroups of Type 1 Diabetes

              Contact the Supplier

              Lead Product(s): GAD-alum

              Therapeutic Area: Endocrinology Product Name: Diamyd

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 05, 2020

              Details:

              Diabetologia published results from a meta study that demonstrates a highly significant and clinically relevant effect of Diamyd Medical's lead drug candidate Diamyd® on preserving endogenous insulin production in genetically defined subgroups of type 1 diabetes.

              PharmaCompass__DigitalAd